首页> 外文OA文献 >Safety, Pharmacokinetics, and Preliminary Activity of CDK4/6 Inhibitor FCN-437c in Chinese Female Patients with HR+HER2- Advanced Breast Cancer (ABC) From Phase Ia Study

【2h】

Safety, Pharmacokinetics, and Preliminary Activity of CDK4/6 Inhibitor FCN-437c in Chinese Female Patients with HR+HER2- Advanced Breast Cancer (ABC) From Phase Ia Study

机译：CDK4 / 6抑制剂FCN-437C在中国女性HR +海拔乳腺癌（ABC）中的CDK4 / 6抑制剂FCN-437C的安全性，药代动力学和初步活动来自IA期的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Jian Zhang; Xiaojia Wang; Xian Wang; Aimin Hui; Zhuli Wu; Ling Tian; Changjiang Xu; Yuchen Yang; Wenjing Zhang; Xichun Hu;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate [J] . Lillian S., De Bono J., Higano C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：AZD8186研究1：I期研究评估AZD8186在晚期去势抵抗性前列腺癌（CRPC），鳞状非小细胞肺癌患者中的安全性，耐受性，药代动力学（PK），药效学（PD）和初步抗肿瘤活性，三联阴性乳腺癌以及PTEN缺陷/突变或PIK3CB突变/扩增的恶性肿瘤，单药治疗并与vistusertib（AZD2014）或醋酸阿比特龙合用
2. AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate [J] . Lillian S., De Bono J., Higano C., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：AZD8186研究1：I期研究，评估AZD8186在先进的阉割前列腺癌（CRPC），鳞状非小细胞肺癌患者中AZD8186的安全性，耐受性，药代动力学（PK），药效学（PD）和初步抗肿瘤活性，三重阴性乳腺癌和PTEN缺乏/突变或PIK3CB突变/扩增的恶性肿瘤，作为单药治疗，与Vistusertib（AZD2014）或乙酸酯组合
3. Neoadjuvant capecitabine (X), docetaxel (T)±trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy data from a multicentre phase II study [J] . W.Lybaert, Wildiers, P.Neven, European Journal of Cancer Supplements . 2006,第2期

机译：新辅助卡培他滨（X），多西他赛（T）±曲妥珠单抗（H）用于局部晚期乳腺癌（LABC）的患者（pts）：一项来自多中心II期研究的初步安全性和有效性数据
4. Stilbene analogues as inhibitors of breast cancer Stem cells through P-glycoprotein efflux; A 3D quantitative structure-activity relationship study (Inhibitory activity of stilbenes analogues on breast cancer stem cells) [C] . Anushree Tripathi, Krishna Misra 2016 International Conference on Bioinformatics and Systems Biology . 2016

机译：Stilbene类似物通过P-糖蛋白外排作为乳腺癌干细胞的抑制剂； 3D定量结构-活性关系研究（Stilbenes类似物对乳腺癌干细胞的抑制活性）
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. A first-in-Asian phase 1 study to evaluate safety pharmacokinetics and clinical activity of VS-6063 a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors [O] . Toshio Shimizu, Kazuya Fukuoka, Masayuki Takeda, -1

机译：亚洲第一项第一阶段研究旨在评估日本晚期实体瘤患者中粘着斑激酶（FAK）抑制剂VS-6063的安全性药代动力学和临床活性
7. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors [O] . 2016

机译：亚洲第一项第一阶段研究，旨在评估日本晚期实体瘤患者中粘着斑激酶（FAK）抑制剂VS-6063的安全性，药代动力学和临床活性

Safety, Pharmacokinetics, and Preliminary Activity of CDK4/6 Inhibitor FCN-437c in Chinese Female Patients with HR+HER2- Advanced Breast Cancer (ABC) From Phase Ia Study

著录项

相似文献

相关主题

期刊订阅